2016 American Transplant Congress
The Coefficient of Variability of Tacrolimus Levels Can Predict Antibody-Mediated Rejection After Renal Transplantation.
Introduction. Antibody-mediated rejection (ABMR) is the major cause of allograft failure. We studied whether the coefficient of variability (CV) of blood levels of tacrolimus can…2016 American Transplant Congress
The Effect of Tocilizmab Treatment (TCZ-Rx) on Total IgG and Anti-CMV-IgG Levels in HLA-Sensitized (HS) Kidney Transplant Patients.
Background: TCZ has anti-B cell and anti-inflammatory properties. We have reported its successful use for pre-transplant (Tx) desensitization (DES) and treatment of ABMR. We also…2016 American Transplant Congress
Effect of Donor-Recipient Gender Mismatch in Liver Transplant Recipients: A Post-Hoc Analysis of the H2304 Study.
H2304 study group, Hamburg, Germany.
Purpose: Donor-recipient gender mismatch may play a role in liver transplant (LTx) outcomes. Here we present the 24-month results from the post-hoc analysis of the…2016 American Transplant Congress
Pulse Wave Velocity Amongst African-American Kidney Transplant Recipients Randomized to Once-Daily MeltDose Tacrolimus Tablets (Envarsus XR) vs. Traditional Twice-Daily Tacrolimus Capsules: Exploratory Results from a Phase III Trial.
Cardiovascular (CV) death is a leading cause of death in kidney transplant recipients (KTR). Increased aortic arterial stiffness is strongly associated with the development of…2016 American Transplant Congress
Variation in Co-Medication Use According to Kidney Transplant Immunosuppressive Regimen: Application of Integrated Registry and Pharmacy Claims Data.
Background: While modern immunosuppressive therapies (ISx) have substantially reduced acute rejection, ISx medications have many side effects, and transplant recipients must take an array of…2016 American Transplant Congress
Efficacy and Renal Function in Kidney Transplant Recipients Receiving Tacrolimus (TAC)-Based Immunosuppressive Regimens in Combination with Everolimus (EVR) versus Mycophenolate (MPA).
Nephrology Division, Hospital do Rim - UNIFESP, Sao Paulo, Brazil.
Acute rejection and renal function are associated with long-term renal allograft survival. We evaluated these outcomes in patients receiving reduced TAC exposure combined with EVR…2016 American Transplant Congress
Impact on Renal Function of Stepwise Withdrawal of Tacrolimus Combined with Everolimus and EC-MPS vs Standard Treatment Combining Tacrolimus and EC-MPS in De Novo Liver Transplant Recipients: Results of the SIMCER Study.
Introduction: Long-term post-liver transplant (LTx) complications, particularly impaired renal function (RF) and its consequences, remain a concern. Presented here are the results of the SIMCER…2016 American Transplant Congress
Ibrutinib Suppresses Alloantibody Responses in A Mouse Model of Allosensitization: A Preliminary Report.
CTC/Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Background Ibrutinib is a Bruton tyrosine Kinase (BTK) antagonist that inhibits B cell receptor (BCR) signaling, therefore blocking B cell activation. Ibrutinib is approved by…2016 American Transplant Congress
Refill-Based Immunosuppression Non-Adherence Is Associated with Increased Death Censored Graft Loss.
Medicine, University of Alberta, Edmonton, AB, Canada.
Introduction Medication non-adherence is a major contributor of graft loss in kidney transplant(KTX) recipients. We aim to evaluate the association of immunosuppression non-adherence to graft…2016 American Transplant Congress
Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients.
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…
- « Previous Page
- 1
- …
- 107
- 108
- 109
- 110
- 111
- …
- 138
- Next Page »